Compare MPV & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPV | KRRO |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.5M | 150.0M |
| IPO Year | N/A | 2019 |
| Metric | MPV | KRRO |
|---|---|---|
| Price | $16.49 | $10.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $34.80 |
| AVG Volume (30 Days) | 11.8K | ★ 123.0K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | N/A | ★ $6,392,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.71 | ★ N/A |
| Revenue Growth | N/A | ★ 181.46 |
| 52 Week Low | $15.65 | $5.20 |
| 52 Week High | $21.00 | $55.89 |
| Indicator | MPV | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 34.26 | 41.32 |
| Support Level | $16.06 | $9.51 |
| Resistance Level | $17.53 | $14.42 |
| Average True Range (ATR) | 0.32 | 0.99 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 0.00 | 31.01 |
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.